Radiopharm Theranostics Limited
Radiopharm Theranostics Limited (RADX) Revenue
Annual & quarterly revenue history · segment & region breakdown
RADX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsRadiopharm Theranostics Limited trailing twelve-month (TTM) revenue is $0.00B, an increase of 1114.27% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2022 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-06-30 | $0.00B | +$0.00B | +1114.27% |
| 2024-06-30 | $0.00B | +$0.00B | +2.35% |
| 2023-06-30 | $0.00B | +$0.00B | +3210.60% |
| 2022-06-30 | $0.00B | — | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Radiopharm Theranostics Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Radiopharm Theranostics Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in AUD.
Data sourced from Radiopharm Theranostics Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
RADX revenue · 4 questionsRADX's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 1114.27% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Radiopharm Theranostics Limited SEC filings · GAAP · Radiopharm Theranostics Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026